Search Medical Condition
Please enter condition
Please choose location

Centennial, Colorado Clinical Trials

A listing of Centennial, Colorado clinical trials actively recruiting patient volunteers.

RESULTS

Found (241) clinical trials

Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial

The study is a prospective, open-label, non-controlled, single-arm, multicentre phase III study. Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2 ...

Phase

0.0 miles

Learn More »

Randomized Placebo-controlled Multi-dose Study Comparing Budesonide/Formoterol to Symbicort in Asthmatic Patients

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and ...

Phase

0.0 miles

Learn More »

A Phase 3 Multinational Multicenter Open-Label Study of ProMetic BioTherapeutics IVIG

A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases (PIDD) to assess the tolerability, safety, efficacy and pharmacokinetics of ProMetic's IGIV in subjects with PIDD. IGIV is intended for ...

Phase

1.27 miles

Learn More »

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).

Phase

1.27 miles

Learn More »

An Open Label Study of CM-AT for the Treatment of Children With Autism

Autism is clearly a significant cause of disability in the pediatric population. Treatment is based on the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a granulated powder taken three times daily.

Phase

1.27 miles

Learn More »

Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis

A total of 295 patients will be enrolled for this study. All potential patients being considered for the study should have been diagnosed with significant carotid artery stenosis and be considered a high perioperative risk for carotid endarterectomy. Patients will be evaluated through screening, pre-procedure, index procedure, post-procedure. Follow-up visits ...

Phase N/A

1.27 miles

Learn More »

A Study of Abemaciclib (LY2835219) in Women With HR+ HER2+ Locally Advanced or Metastatic Breast Cancer

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant or chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies ...

Phase

1.27 miles

Learn More »

A Phase 3 Trial of the Safety Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a ...

Phase

1.27 miles

Learn More »

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

This is a randomized, double-blind, double-dummy, active comparator-controlled, parallel-group, multicenter study with variable treatment duration in approximately 900 patients with relapsing MS. The maximal treatment duration in the study for an individual patient will be 2.5 years. Eligible patients will be randomized to receive either experimental ofatumumab subcutaneous (sc) injections ...

Phase

1.27 miles

Learn More »

Randomized Placebo-controlled Multi-dose Study Comparing Budesonide/Formoterol to Symbicort in Asthmatic Patients

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and ...

Phase

1.27 miles

Learn More »